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Summary 
Sarcopenia represents a major health problem highly
prevalent in elderly and age-related chronic diseases.
Current pharmacological strategies available to prevent
and reverse sarcopenia are largely unsatisfactory thus
raising the need to identify novel targets for pharmaco-
logical intervention and possibly more effective and safe
drugs. This review highlights the current knowledge of
the potential benefits of renin-angiotensin system block-
ade in sarcopenia and discuss the main mechanisms un-
derlying the effects.
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Introduction
Sarcopenia represents a major health problem and a leading
cause of disability, morbility and mortality. It currently affects
almost 50 million people worldwide, with estimates of growth
to 500 million people in the year 2050 (1, 2). Prevalence of
sarcopenia increases substantially with age, being one of the
main components in the development of frailty. However, it is
still unknown whether sarcopenia in elderly is an inevitable
consequence of aging or is the result of a combination of dif-
ferent causative factors. Among them, highly prevalent co-
morbidities in elderly, including chronic obstructive pul-
monary disease, diabetes, hypertension and heart failure,
most organ failures, and cancer, promote muscle wasting
and the occurrence of frailty. Therefore, the identification of
effective strategies to prevent and/or treat sarcopenia, has
great importance to support healthy ageing and lower the im-
pact of frailty associated with age-related chronic diseases.
On the other hand, sarcopenia may also be caused by
chronic drug treatment and at the same time it modifies the
pharmacokinetic of drugs thereby decreasing their risk to
benefit balance (3). 
Despite criteria for diagnosing still remain approximate,
pathophysiological hallmarks of sarcopenia are better identi-
fied (1, 2). It is defined as progressive and generalized im-
pairment in skeletal muscle strength caused by muscle fibre
loss and modifications of muscle quality. In particular, there
is evidence documenting a preferential decrease of fast
twitch (type II) fibres and a relative increase of the slower
(type I) ones. These modifications often are associated with
alterations in excitation-contraction properties, such as calci-
um cycling and handling and other dysfunctional events
caused by mitochondrial dysfunctions, metabolic disorders,
insulin resistance, lipodistrophy and increased tissue fibro-
sis. Altogether these changes contribute to decline maximal
muscle strength, reducing mainly explosive power but also
increasing muscle fatigability.
Multiple risk factors may predispose to develop sarcopenia
and likely cooperate with each other contributing to deter-
mine the severity and the reversibility of the condition (4).
They include the age-related increase of insulin resistance
and the decline of different hormones (e.g. estrogens, andro-
gens and growth hormone) and vitamin D. Furthermore,
muscle detrimental effects are also induced by pro-inflamma-
tory cytokines (e.g. Il-6 and Il-1) that consistently increase
with age, especially in the presence of age-related chronic
diseases. Other causative factors include physical inactivity
and poor diet, which are pivotal determinants of loss of mus-
cle mass and strength regardless of age. Finally, genetic
predisposition also plays a role and likely accounts for inter-
individual variations and differences of prevalence among
ethnic groups. 
To date, few mechanisms have been proposed to mediate
the onset and the progression of sarcopenia. Among them,
the alteration of metabolic homeostasis and the decreased
sensitivity to insulin are hypothesized to imbalance protein
turnover in the muscle, favoring protein degradation and fi-
bre wasting. Interestingly, a recent hypothesis shifts the at-
tention from muscle fibre to satellite cells, resident precur-
sors in the muscle that, following recruitment after injury, un-
dergo proliferation and differentiation aimed to regenerate
the tissue (5). The pool of satellite cells is depleted by age-
ing and age-related comorbities, thereby declining muscle
regeneration capacity and susceptibility to injuries and sar-
copenia. 
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Identification of effective and safe therapeutic strategies in sar-
copenia is an open and rather neglected field of investigation.
While the stimulation of satellite cells and/or progenitors trans-
plantation still remain a fascinating approach, current pharma-
cological strategies available to prevent and reverse sarcope-
nia are largely unsatisfactory in terms of choice, efficacy and
occurrence of adverse reactions. Among the pharmacological
interventions different drugs are used, with limited clinical effi-
cacy in relieving sarcopenia (6). Recently, experimental and
clinical studies have given interesting insights on role of the
renin-angiotensin system (RAS) in the skeletal muscle, sug-
gesting a potential benefit of angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptor blockers (ARB) in
sarcopenia. 
In this review, we briefly highlight current knowledge of the
physiological role of RAS in skeletal muscle. We then pro-
vide an overview of the potential benefits of ACE inhibitors
and ARB in sarcopenia; finally, we discuss the main mecha-
nisms underlying the effects. 
RAS in skeletal muscle
In mammals, the endocrine RAS plays a fundamental role in
circulatory homeostasis by regulation of blood pressure, fluid
and salt balance. Circulating renin is a protease that cat-
alyzes the conversion of hepatic angiotensinogen to an-
giotensin I, a decapeptide. This is further converted into an-
giotensin II (Ang II), an octapeptide, by ACE, an endothelial
peptidase primarily found within the pulmonary bed and the
lung. Ang II is the main effector of RAS that through interac-
tion with specific receptors, particularly its type 1 receptor
(AT1R), causes direct vasoconstriction as well as salt and
water retention as a consequence of adrenal aldosterone re-
lease. Beyond ACE, evidence indicates that a different en-
zyme, ACE2 negatively modulates the activated RAS by
cleaving Ang II to the heptapeptide Ang (1-7). The latter acts
through the type 2 receptor (AT2R) and Mas receptor and
counterbalances at least part of cardiovascular effects of
Ang II by opposing many of the actions mediated by AT1R
activation (7-9). Furthermore, ACE converts a different pep-
tide, bradykinin, which exerts a potent vasodilatory effect via
activation of bradykinin type-1 and 2 receptors (BK1R, and
BK2R, respectively). At tissue and cellular level, function of
RAS may be further complex due to the interplay with local
or tissue-based RAS. The latter integrates or complements
systemic Ang II and exerts paracrine and autocrine functions
mostly related to tissue growth and injury responses. 
Recent evidences have focused the attention on the physio-
logical role of RAS on skeletal muscle, a target organ largely
ignored for Ang II effects. Regulation of local perfusion aris-
ing from systemic Ang II is fundamental to regulate metabol-
ic activity and function of skeletal muscle. In addition to this,
recent experimental studies (10, 11) document supplemen-
tary effects induced by Ang II and downstream receptors
mostly related to tissue trophysm and regenerative capacity.
Indeed, in animal models the increase of Ang II levels
proved to induce skeletal fibre wasting through enhanced
protein degradation and apoptosis as well as decreased pro-
tein synthesis. Part of these detrimental effects of Ang II are
mediated directly by AT1R expressed at skeletal muscle lev-
el. Moreover, indirect and negative effects are also provided
by intermediate molecules (e.g. cytokines and glucocorti-
coids), which are released from different sources upon in-
creased Ang II levels. In line with the detrimental effects of
RAS activation observed in animal models, patients with
cachexia and  characterized by extensive muscle loss,  also
display elevated levels of circulating Ang II (12). 
Different studies in humans have demonstrated that reduced
expression of ACE because of a genetic polymorphism is as-
sociated with greater muscle anabolic response and im-
proved skeletal muscle performance after training (13). It has
been suggested that part of the association of ACE genotype
with performance phenotype is mediated by modulation of
kinin levels and kinin activity at BK2R. However, a beneficial
role on muscle trophysm induced by the decrease of Ang II
levels and the reduction of AT1R activation may also be hy-
pothesized to concur to the enhanced muscle performance. 
Despite further studies are necessary, together these evi-
dence concur to identify RAS and downstream receptors as
important regulatory axis in skeletal muscle physiology. The
negative effects provided by ANGII/AT1R system represent
a basis for a pharmacological approach to RAS blockade po-
tentially useful in sarcopenia. 
Effects of RAS blockade in sarcopenia
Different observational data suggest that in cardiovascular
patients ACE inhibitors and ARB may improve the decline of
muscle performance and reduce the occurrence of frailty (12,
14, 15). Because both classes of drugs share the capacity to
decrease the bioavailability and/or the biological activity of
Ang II, these evidence led to consider the possibility that re-
duced levels of Ang II or RAS blockade may slow-down mus-
cle wasting with potential implication for therapy. Interesting-
ly, one of the study performed in cardiovascular patients
treated with ACE inhibitors and ARB has demonstrated that
the enhanced muscle performance is associated with a key
molecular modification of myosin heavy chain, one of the
sarcomeric protein in skeletal muscle (16). In fact, while the
fast oxidative and glycolytic proteins (MHC2B and 2A) are
prominent in the sarcopenic patients, after drug administra-
tion they decline and appear to be shifted toward the slow,
more fatigue-resistant isoform (MHC1). These results corrob-
orate the concept that RAS inhibition may directly ameliorate
the function of skeletal muscle counterbalancing some of the
biochemical and structural changes occurring in sarcopenia.
In line with data observed in cardiovascular patients, in a rat
model of heart failure associated with muscle atrophy and in-
creased fatigability, protective effects of AT1R blockers are
also documented and further proved to reverse most of the
molecular markers of skeletal muscle wasting (17). 
Despite the mechanisms of action of RAS blockade are still
controversial, one of the hypothesis is that the benefit on
cardiac output and that on hemodynamic parameters could
promote skeletal muscle blood supply with positive conse-
quences on muscle metabolism and function. Moreover,
ACE inhibitors are also known to improve endothelial func-
tion, enhance muscle glucose uptake, increase potassium
levels and modulate other hormonal systems including insu-
line-like growth factor-1, all of which could contribute to im-
prove skeletal muscle function. Finally, a direct trophic effect
of RAS blockade in skeletal muscle is supported by different
studies on animal models, which provide the opportunity to
evaluate the efficacy of RAS blockade on sarcopenia in the
absence of cardiovascular diseases. In the setting of muscle
atrophy induced by aging (18) or myopathic states (19), ARB
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resulted to be protective against muscle wasting and attenu-
ated failure of muscle regeneration. 
Following on from these data, a small randomised controlled
trial evaluated the effect of ACE inhibitors on physical func-
tion in geriatric patients with impairment of daily activities
(20). The intervention group achieved a consistent improve-
ment of muscle performance equivalent to that reported after
six months of exercise training. Larger clinical studies are
necessary to verify and extend these results.
Recently, a novel mechanism of action for ACE inhibitors and
ARB on skeletal muscle has been postulated and partially veri-
fied in animal models. The attention was focused on muscle
satellite cells as main target of RAS activation or blockade (Fig-
ure 1). In these studies Ang II/AT1R axis resulted to reduce
satellite cell migration, differentiation and growth (10, 11, 21),
fundamental requisites of satellite cells aimed to sustain mus-
cle regeneration after injuries and fibre wasting. Blockade of
RAS resulted to protect the pool of satellite cells promoting
muscle regeneration and function improvement. Of note, be-
cause of AT1R blockade, part of the observed effects may de-
rive from a local shift of Ang II towards muscle AT2R, whose
activity is expected to counterbalance that of AT1R activation
(Figure 1). Moreover, in the presence of ACE inhibitors Ang II
is preferentially degraded by ACE2 that through activation of
Ang (1-7)/Mas receptor axis shares a pharmacodynamic profile
similar to that of AT2R activation and opposes many of the ac-
tions mediated by AT1R (7). Accordingly, in the mouse Ang (1-
7) proved to promote muscle regeneration by activating satel-
lite cell growth and differentiation (22, 23). Whether similar
mechanisms occur in humans or in human cells after RAS
blockade are presently unknown and represent an important is-
sue to be addressed.
Summary and conclusion
Accumulating evidence have identified RAS as an important
regulator of the skeletal muscle, being involved in physiologi-
cal functions including perfusion, trophism and regeneration
capacity. Parallel studies have documented the potential
benefits of RAS blockade in different pathologic conditions
including sarcopenia and uncovered a positive modulatory
role exerted by Ang (1-7) peptide that would activate the
“good arm” of RAS. 
Despite the progresses made, numerous key questions on
the benefits of RAS blockade in sarcopenia still remain
unanswered and deserve thorough investigations both in the
experimental and clinical setting. If the role of Ang (1-7) in
muscle wasting would be confirmed, the peptide and its
downstream receptors (AT2R and MAS receptor) might rep-
resent novel targets of the RAS axis useful to preserve the
pool of satellite cell inside the skeletal muscle and their re-
Figure 1 - Schematic representation of RAS axis and of the effect on skeletal muscle. 
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generative potential in sarcopenia or after muscle injuries. In
this context, the identification of selective and stable ago-
nists for Mas receptors would be a valuable achievement as
well as the use of selective agonists for AT2R, which are
currently the object of researches mainly restricted to the
cardiovascular field (24).
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